New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies Read more about New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
Amgen To Present At The Morgan Stanley Global Healthcare Conference Read more about Amgen To Present At The Morgan Stanley Global Healthcare Conference
Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma Read more about Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma
European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis Read more about European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma Read more about Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label Read more about FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label
New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition Read more about New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition
New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke Read more about New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke
New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels Read more about New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels
Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020 Read more about Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020
